Autopsy report · NCT01289678

Trial of Daily Pulse Interleukin-2 With Famotidine in Acute Myelogenous Leukemia

“Unable to meet accrual goals”

The sponsor’s own words in the registry.

Life of this trial

• Registered 4 years 7 months after it had already started.
• Ran for about 10 years 2 months before it stopped.
• 18 participants enrolled.
• Results were posted on the registry 3 years after it ended.

Vital statistics

Status

Terminated

Phase

Phase 2

Sponsor

Leo W. Jenkins Cancer Center

Sponsor type

University, hospital or other

Conditions

Acute Myelogenous Leukemia

Interventions

Interleukin-2

Participants

18

Sites

1

Countries

United States

Trials that died the same way

• Afatinib in Advanced Refractory Urothelial Cancer
  “Unable to meet accrual goal after several years” (87% match in meaning)
• Pilot Study of Cabozantinib for Recurrent or Progressive Central Nervous System Tumors in Children
  “Failure to meet accrual goals.” (79% match in meaning)
• A Randomized Study of the Site for Growth Factor Injection for Patients Undergoing Autologous Stem Cell Transplantation
  “Accrual goal met” (75% match in meaning)
• Study of Pemetrexed and Gemcitabine for Patients With a New Diagnosis of Extensive-Stage Small Cell Lung Cancer
  “failure to accrue” (71% match in meaning)
• Detection of Tumor DNA in Blood Samples From Patients With Early Stage Cancer and "Healthy Controls"
  “Accrual difficulties” (71% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.